Margetuximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | HER2 |
| Clinical data | |
| Trade names | Margenza |
| Other names | margetuximab-cmkb, MGAH22 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | HER2/neu receptor antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6484H10010N1726O2024S42 |
| Molar mass | 145873.98 g·mol−1 |
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.[3][4]
The most common adverse drug reactions in combination with chemotherapy are fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar erythrodysesthesia, and extremity pain.[2]
This drug was created by Raven biotechnologies, which was later acquired by MacroGenics. It was engineered to increase affinity for CD16A polymorphisms and decrease affinity for FcγRIIB (CD32B), an inhibitory receptor.[4]
It binds to the same target (epitope) as trastuzumab,[5] on the HER2 receptor.
- ^ a b "Margenza FDA label" (PDF).
- ^ a b "FDA approves margetuximab for metastatic HER2-positive breast cancer". U.S. Food and Drug Administration (FDA). 16 December 2020. Retrieved 25 December 2020. This article incorporates text from this source, which is in the public domain.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Margetuximab, American Medical Association.
- ^ a b "Margenza". NCI Drug Dictionary. National Cancer Institute. Retrieved 17 December 2020.
- ^ "Pegram Discusses Promise of Margetuximab/Chemo Combo for HER2+ Breast Cancer. Jan 2017". Archived from the original on 2018-07-31. Retrieved 2017-02-27.